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ABSTRACT 
The identification of the brain structures and neurotransmitters responsible for the generation and/or modulation 
of the mismatch negativity (MMN) may contribute to a clearer understanding of its functional significance, and 
may have clinical implications. In this context, some findings suggest that the scalp-recorded MMN reflects 
activity from multiple neuronal ensembles within or in the immediate vicinity of the primary auditory cortex and 
with possible contribution from the frontal cortex. However, few data are available concerning the influence of 
neurotransmitter systems on the MMN. In this study, the relationship between both noradrenergic and 
dopaminergic systems and the MMN were investigated in 34 healthy volunteers. Noradrenergic and 
dopaminergic activities were assessed with the apomorphine and clonidine challenge tests. The results showed 
no significant relationship between either growth hormone (GH) responses to apomorphine or clonidine and the 
MMN amplitude or latency. Therefore, this study does not demonstrate the implication of dopaminergic and 
noradrenergic activities as assessed by GH response to apomorphine and clonidine for the generation and/or the 
modulation of the MMN. However, given the complexity of the central neurotransmitter systems, these results 
cannot be considered as definitive evidence against a relationship between dopaminergic and noradrenergic 
activity and the MMN. 
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INTRODUCTION 
The mismatch negativity (MMN) is a fronto-central component of the auditory event-related brain potential 
(ERP) elicited by a physically deviant auditory stimulus occurring among frequent stimuli with a latency of 
about 130 ms from stimulus onset and lasting to about 250/300 ms (Näätänen et al., 1978; Näätänen, 1990, 1995, 
2001; Picton et al., 2000). The MMN is presumably generated by a mismatch process between the sensory input 
from a deviant stimulus and a short-term memory (sensory-memory) trace representing the physical features of 
the standard stimuli. This process appears to be automatic since the 
MMN is elicited even by changes in unattended auditory stimuli. Therefore, the MMN is considered as a 
neurophysiological index of early sensory processing and automatic attention (involuntary attention) and is 
related to the orienting reflex (Näätänen, 1990, 1995). Few data are available concerning the influence of 
neurotransmitter systems on the MMN. In a single-blind placebo-controlled study, Umbricht et al. (2000) have 
suggested that N-methyl-D-aspartate receptors (NMDAR) were critically involved in the human MMN because 
the NMDAR antagonist keta-mine significantly decreased the peak amplitude of the MMN. These results 
indicated that glutamatergic activity could be involved in the genesis of the MMN. However, in a double-blind 
randomized placebo-controlled study, ketamine did not alter the MMN (Oranje et al., 2000). Recently, Hirvonen 
et al. (2000) have demonstrated that adenosine A1 and A2a receptors played a role in the generation of the 
MMN. Moreover, some drugs which induce reduced arousal (e.g. naltrexone and nitrous oxide) decreased the 
MMN amplitude (Jaaskelainen et al., 1998; Pang and Fowler, 1999), whereas some drugs which enhance 
memory function (e.g. vasopressin) increased the MMN amplitude (Born et al., 1998). Moreover, the attenuation 
of the MMN by triazolam and chlorpheniramine suggested respectively a GABAergic and a histaminergic 
implication in the genesis of the MMN (Serra et al., 1996; Nakagome et al., 1998). 
Another way, other than psychopharmacological studies, to assess the implication of neurotransmitters in the 
genesis of the MMN is neuroendocrine challenge tests (Lal et al., 1972; Matussek et al., 1980; Checkley et al., 
1981; Ansseau et al., 1988; Hansenne et al., 1992; Pitchot et al., 1992). In the present study, apomorphine and 
clonidine tests were used to assess the implication or not of the dopaminergic and the noradrenergic systems in 
the generation and/or the modulation of the MMN. It is reasonable to expect an association between 
dopaminergic activity and the MMN since both parameters are altered in psycho-pathological conditions such as 
schizophrenia where the impairment of the MMN is partly determined by alteration of the dopaminergic activity 
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(Catts et al., 1995; Willner, 1997; Oades et al., 1997; Javitt, 2000). 
METHODS 
Thirty-four healthy subjects (15 women and 19 men, mean age of 28.5 ±9.2 years) recruited among the staff of 
the University Hospital of Liège (Belgium) participated in the study. They were paid for their participation (250 
Euro). They all underwent a medical interview by a physician (AC) to exclude psychiatric or somatic disorders. 
Moreover, all subjects had a body mass index (BMI) of between 20 and 25 (Bray, 1978; Thomas et al., 1976). 
The Ethical Committee of the University of Liège Medical School approved the protocol and all subjects gave 
their informed consent. 
The MMN recording was carried out in a sound-attenuated room. The subjects were tested until a total of 150 
tones was obtained after rejecting trials for eye movement or other artifacts. The auditory stimuli were presented 
binaurally in a random series at the rate of one trial every second. The standard stimuli were tones of 1470 Hz, 
70 dB and 40 ms duration, and the other 20% (deviant) were tones of 1470 Hz, 70 dB, 80 ms duration. To be 
sure that the subjects were distracted from the task, they were instructed to perform arithmetic operations during 
the experiment. 
The EEG was recorded with silver-silver chloride electrodes attached at Fz, Cz and Pz using linked ear-lobes for 
reference and right forehead for ground. All sites were cleaned with acetone and abraded to maintain a resistance 
below 5 kOhms. EOG was recorded from above the left eye. Amplifier gains were set at 10000, with a band pass 
of 0.05-35 Hz. The EEG was digitized at 250 sample/s for 900 ms with a 100 ms prestimulus baseline. Trials in 
which the EEG or EOG exceeded 50 µV were rejected automatically. 
The MMN amplitude and latency were measured as the difference in voltage between the baseline and the higher 
point between 150 and 260 ms after the stimulus onset for the difference wave where averaged ERPs to 
standards were subtracted from responses to deviants. 
Clonidine and apomorphine tests were performed at 1 day intervals within the same week as the MMN 
recording, both after an overnight fast using a procedure previously described (Ansseau et al., 1988). Due to the 
influence of oestrogens on growth hormone secretion (Tulandi et al., 1987), only premenopausal women were 
included and the challenge tests were performed between days 3 and 12 of the menstrual cycle. Briefly, at 0800 
h, a butterfly needle was inserted into a forearm vein. Blood samples of 10 ml were collected 20 min before and 
immediately before the injection of clonidine or apomorphine at 0830 h. Successive blood samples were 
collected 20, 40, 60 and 120 min after the injection. Clonidine (0.15 mg), diluted in saline to obtain 20 ml, and 
apomorphine (0.5 mg), diluted in saline to obtain 0.5 ml, were injected, respectively, iv in 10 min and sc. Blood 
samples were immediately centrifuged, and plasma was frozen and kept at -18°C until analysis. 
Growth hormone was measured with a double antibody radioimmunoassay with intra-assay and inter-assay 
coefficients of variation of 13.3 ± 4.7% and 14.8 ± 9.6%, respectively, and a detection limit of 0.1 mUI/ml. 
Growth hormone responses to clonidine and apomorphine were assessed by the area under the curve (AUC) 
situated between injection (t0) and the last blood sample (tl20). Both measures were performed with absolute and 
relative values (absolute values minus baseline). Since absolute and relative values were highly correlated               
(r < 0.97), only absolute AUC values are reported here. 
The statistical analyses were performed using Statistica (4.5) for Windows (Statsoft Inc 1993). The relationships 
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Figure 1.    Illustrative event-related potentials elicited by frequent (thin lines) and deviant tones (thick lines), 
and the respective potential differences (i.e. the subtracted responses, dashed lines) in two subjects 
 
RESULTS 
Figure 1 presents two illustrative ERP recordings obtained in two subjects. The mean MMN amplitude was -5.6 
µV at Fz (SD = 2.9), -5.5 µV at Cz (SD = 3.2) and -4.5 µV at Pz (SD = 2.8). Mean MMN latency was 224 ms at 
Fz (SD = 20.5), 222 ms at Cz (SD = l8.l) and 226ms at Pz (SD = 17.6). Growth hormone  response  to  
apomorphine   and  clonidine calculated as the area under the curve (AUC) ranged respectively from 22.7 to 
4638 IU min/ml and from 19.2 to 4496 IU min/ml with mean values of 1022.3 (SD = 956.5) and 1175.8 (SD = 
1128.2). 
Spearman rank order correlation coefficients and probability values are presented in Table 1. No significant 
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Table 1. Spearman rank order correlation coefficients (r) and probability values (p) between growth hormone 
(GH) response to apomorphine and clonidine tests (AUC values) in 34 healthy controls 
  GH response to apomorphine GH response to clonidine 
MMN amplitude Fz -0.15 (p = 0.39) -0.01 (p = 0.94) 
 Cz -0.16 (p = 0.38) 0.03 (p = 0.87) 
 Pz -0.19 (p = 0.27) -0.09 (p = 0.61) 
MMN latency Fz -0.05 (p = 0.79) 0.27(p = 0.13) 
 Cz 0.03 (p = 0.89) 0.23 (p = 0.19) 
 Pz 0.01 (p = 0.99) 0.22 (p = 0.21) 
 
DISCUSSION 
The results of this study did not demonstrate the implication of dopaminergic and noradrenergic activities as 
assessed by GH response to apomorphine and clonidine for the generation and/or the modulation of the MMN. 
However, if neuroendocrine strategy constitutes a relevant index of central neurotransmission, it exhibits 
limitations. Indeed, the apomorphine induces GH secretion by affecting the tuberoinfundib-ular dopaminergic 
system (Sourkes and Lal, 1975). Moreover, it is possible that the hypothalamo-pitui-tary GH secretory 
responsiveness and neocortical excitation by deviant stimuli are in fact separately regulated with regard to both 
dopaminergic and noradrenergic activation. In consequence, it should be noted that the study did not determine 
the direct effects of apomorphine and clonidine on the MMN. 
A serious limitation of the study is that it can provide only limited information given the fact that the MMN 
recording and both apomorphine and clonidine challenges were not caried out consecutively on the same day. 
Indeed, there are many short-term changes in the noradrenergic and dopaminergic neurotransmissions implying 
that both noradrenergic and dopaminergic activities during the challenges may not be comparable to the day 
when the MMN was recorded. However, several lines of evidence have shown that the clonidine test may 
represent a stable trait and a single assessment seems to be sufficient for investigating central noradrenergic 
activity (Mitchell et al., 1988; Trestman et al., 1994). 
In the present study, dopaminergic activity as assessed by GH response to apomorphine was not implicated in 
the generation and/or the modulation of the MMN. However, two reasons would have justified an association 
between dopaminergic activity and the MMN. The first reason is that the MMN reflects automatic attention 
processes and that several data suggest that dopaminergic agonists enhance attentional processes and arousal 
(Solanto, 1998). An association between dopaminergic activity and the MMN can reasonably postulated. A 
speculative explanation of the lack of an association between the MMN and dopamine is that dopaminergic 
activity is not implicated in automatic attentional processes but only in controlled attentional processes. In this 
direction, clozapine improved electrophysiological measures of controlled processes (i.e. P300 amplitude 
increasing), but did not ameliorate preattentive deficits (i.e. the MMN) in schizophrenic patients (Umbricht et al., 
1998). 
The second reason which can justify a possible association between the MMN and dopaminergic activity comes 
from the findings observed in schizophrenia. In fact, several studies have demonstrated that the MMN is 
impaired in schizophrenic patients (Catts et al., 1995; Javitt et al., 1995, 1997; Javitt, 2000), and one robust 
finding from biological psychiatry is a disturbed dopaminergic function in this dramatic disease (Willner, 1997). 
Taken together, these findings may suggest that the impairment of the MMN is partly determined by an 
alteration of the dopaminergic activity. Indeed, Oades et al. (1997) have suggested that impaired processing of 
irrelevant stimuli and reduced frontal MMN in nonparanoid schizophrenic patients could reflect reduced 
dopaminergic responsivity. However, no reliable neuroendocrine changes were observed in schizophrenia 
(Mokrani et al., 1995). 
The present results did not suggest an involvement of the noradrenergic system in the genesis of the MMN. Few 
studies have investigated the possible implication of noradrenaline in the generation and/or the modulation of the 
MMN. Mervaala et al. (1993) have studied the effects of acute modulation of central noradrenergic 
neurotransmission on the MMN using a specific alpha-2 antagonist atipamezole in healthy volunteers. In healthy 
subjects, this drug produced evident noradrenergic overactivity. The results showed that atipamezole did not 
modulate the MMN. 
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In conclusion, the present study does not suggest an association between dopaminergic and noradrenergic 
activities and the MMN. However, according to the restrictions mentioned above, these data are not to be 
considered as definitive evidence against the association between the MMN and specific neurotransmitter 
systems. 
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